Amplifon stock holds steady as H1 2026 margins improve

Amplifon stock is trading near the 12 euro mark as investors digest H1 2026 figures showing modest revenue growth and improved profitability, while analysts see upside potential over the next 12 months.

Amplifon stock (ISIN IT0004056880) is quoted at 11.99 EUR as of September 2, 2026, on the Italian stock exchange according to data compiled by Investing.com. The same overview highlights that the stock carries an average 12-month price target of 13.44 EUR, implying upside potential of about 12.1 percent based on current levels.

H1 2026 results show margin progress

According to the H1 2026 earnings call summary presented on the same Investing.com report, Amplifon generated revenue of 606 million EUR in the second quarter of 2026, up 2.2 percent year on year. Within that figure, organic growth reached 4.7 percent, described as the strongest in about two years for the company, indicating that underlying demand for hearing care services is still expanding.

The report notes that Amplifon improved its adjusted EBITDA margin to 25.8 percent in the second quarter of 2026, an expansion of 0.9 percentage points compared with the prior-year period. This margin improvement came even as the company continued its Fit4Growth restructuring program, suggesting that cost discipline and operating leverage are beginning to support profitability.

Cash flow and balance sheet trends in 2026

In the first half of 2026, Amplifon lifted its adjusted free cash flow to 68 million EUR, up from 40 million EUR in the comparable period a year earlier, according to the same H1 2026 summary on Investing.com. That represents an increase of 70 percent, which provides the company with greater financial flexibility for investments and shareholder returns.

The earnings overview also indicates that the company reduced its pro forma net debt to EBITDA ratio to 1.87 times by the end of the first half of 2026, down from 1.92 times at the end of 2025. This modest yet measurable improvement in leverage underlines that Amplifon is gradually strengthening its balance sheet while maintaining growth initiatives.

Analyst view and upside potential

Investing.com’s analyst consensus compiled as of September 2, 2026, shows that six analysts currently rate Amplifon shares as a buy, with none recommending a sell. The same consensus places the average 12-month price target at 13.44 EUR, with estimates ranging from 11.00 EUR on the low side to 16.70 EUR at the high end, indicating a broadly positive medium-term outlook.

Based on the quoted current price of 11.99 EUR and the average price target of 13.44 EUR, the implied upside for Amplifon stock is about 12.1 percent, according to the Investing.com overview. For investors, the key question is whether the company can sustain organic growth above 3 percent and continue to expand margins, as management’s guidance for 2026 suggests.

Hearing solutions and customer offering

Amplifon is best known for its network of hearing care clinics and its range of customized hearing aid solutions, which combine audiological expertise with digital tools for fitting and follow-up. The company emphasises personalized care, including hearing tests, device selection and aftercare, to support long-term customer satisfaction.

Amplifon stock price snapshot

According to the quote page on Investing.com, Amplifon stock trades at 11.99 EUR as of September 2, 2026, on its primary listing in Milan. The same data set describes the technical picture as neutral based on moving average signals, while highlighting that investors currently expect modest upside over the coming year.

Amplifon stock at a glance

• Company: Amplifon S.p.A.
• ISIN: IT0004056880
• Ticker: AMP
• Trading venue: Borsa Italiana
• Price (as of September 2, 2026): 11.99 EUR
• Sector / Industry: Health Care / Health Care Providers and Services
• Index membership: FTSE MIB
• Market capitalization: data based on current price range and outstanding shares, as reflected on major quote platforms
• Next earnings date: October 29, 2026